- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01888445
A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug
December 31, 2019 updated by: Astellas Pharma Inc
A Japanese, Phase 2, Multicenter, Randomized, 4-arm Parallel, Double-blind (Arms 1-3), Open-label (Arm 4), Active-comparator (Darbepoetin Alfa) Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis-dependent Chronic Kidney Disease Patients With Anemia
This study is to evaluate safety and efficacy of intermittent oral dosing of ASP1517 in dialysis chronic kidney disease patients with anemia.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
To evaluate the safety and the dose-response of ASP1517 on hemoglobin (Hb) correction when ASP1517 is applied intermittently in dialysis chronic kidney disease patients with anemia.
To evaluate the treatment effect on Hb maintenance of ASP1517 administered intermittently in dialysis chronic kidney disease patients with anemia.
Study Type
Interventional
Enrollment (Actual)
130
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Chubu, Japan
-
Chugoku, Japan
-
Hokuriku, Japan
-
Kansai, Japan
-
Kanto, Japan
-
Kyushu, Japan
-
Shikoku, Japan
-
Tohoku, Japan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients who diagnosed as a end-stage kidney disease (ESKD) and are receiving stable chronic maintenance dialysis 3 times per week for ≥ 12 weeks
- Patients who are receiving ESA for at least 8 weeks and the dose of ESA is within the dose range of ESA label
- Hb value at screening test is ≥10.0 g/dL
- Receiving hemodialysis via arteriovenous fistula (AVF) or arteriovenous graft (AVG) or via permanent catheter
- Most recent two Hb values before dialysis during washout period must be both <9.5 g/dL and one of two Hb values must be tested on first visit of the week
Exclusion Criteria:
- Proliferative retinopathy, age-related macular degeneration, retinal vein occlusion and/or macular edema that is considered to require treatment
- Immunological disease with severe inflammation as assessed by the Investigator; even if the inflammation is in remission, the subject is excluded (e.g. lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, celiac disease, etc)
- Having a history of gastric/intestinal resection considered influential on the absorption of the drug in the gastrointestinal tract or active gastroparesis
- Uncontrollable hypertension (SBP ≥160 mmHg and DBP ≥110 mmHg, before dialysis, at screening test)
- Congestive heart failure (NYHA classification III or higher)
- Having a history of hospitalization for stroke, myocardial infarction or lung infarction within 24 weeks before 1st registration
- Positive for any of the following: human immunodeficiency virus (HIV); hepatitis B surface antigen (HBsAg); or anti-hepatitis C virus antibody (anti-HCV Ab)
- Anemia other than anemia due to low/absent renal production of EPO (e.g., iron deficiency anemia, hemolytic anemia, pancytopenia, etc)
- Pure red cell aplasia
- Using anabolic androgenic steroid, testosterone enanthate or mepitiostane within 6 weeks before 1st registration
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ASP1517 Low dose group
Participants received an oral dose of ASP1517 three times a week.
|
oral
Other Names:
|
Experimental: ASP1517 Middle dose group
Participants received an oral dose of ASP1517 three times a week.
|
oral
Other Names:
|
Experimental: ASP1517 High dose group
Participants received an oral dose of ASP1517 three times a week.
|
oral
Other Names:
|
Active Comparator: Darbepoetin group
Participants received Darbepoetin alfa intravenously once a week.
|
iv
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of rise in hemoglobin (g/dL/week)
Time Frame: Baseline and at Week-6
|
Baseline and at Week-6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative number of responder patients
Time Frame: up to Week-24
|
Responder is defined as a hemoglobin >10.0 g/dL and an increase in hemoglobin by >1.0 g/dL from baseline
|
up to Week-24
|
Percent of visits at which patients maintain hemoglobin between 10.0-12.0 g/dL after achieving hemoglobin ≥10.0 g/dL for each patients
Time Frame: for 28 weeks after dosing
|
for 28 weeks after dosing
|
|
Percent of patients who maintain hemoglobin between 10.0-12.0 g/dL at each visit
Time Frame: for 28 weeks after dosing
|
for 28 weeks after dosing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 28, 2013
Primary Completion (Actual)
September 15, 2014
Study Completion (Actual)
September 15, 2014
Study Registration Dates
First Submitted
June 25, 2013
First Submitted That Met QC Criteria
June 25, 2013
First Posted (Estimate)
June 27, 2013
Study Record Updates
Last Update Posted (Actual)
January 2, 2020
Last Update Submitted That Met QC Criteria
December 31, 2019
Last Verified
December 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1517-CL-0304
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development.
Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared.
Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
IPD Sharing Time Frame
Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
IPD Sharing Access Criteria
Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data.
The research proposal is reviewed by an Independent Research Panel.
If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Clinical Study Report (CSR)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Anemia Associated With Chronic Renal Failure (CRF)
-
University of Sao Paulo General HospitalUnknownRenal Transplant Rejection | Graft Failure | Transplant; Failure, Kidney | Chronic Renal Failure (CRF)Brazil
-
FibroGenAstraZenecaCompletedAnemia Associated With End Stage Renal DiseaseUnited States
-
FibroGenAstraZenecaCompletedAnemia Associated With End Stage Renal Disease (ESRD)United States
-
Shengzhen Sciprogen Bio-pharmaceutical Co. LtdUnknownPatient of Anemia in Chronic Renal Failure With HemodialysisChina
-
Rennes University HospitalCompletedChronic Renal Failure (CRF)France
-
Helwan UniversityCompletedAnemia of Chronic Kidney Disease | Chronic Renal Failure | Chronic Renal Failure AnemiaEgypt
-
Lundquist Institute for Biomedical Innovation at...CompletedEnd-stage Renal Disease | Chronic Kidney Failure | Disorders Associated With Peritoneal DialysisUnited States
-
University of Sao Paulo General HospitalCompletedRenal Transplantation | Chronic Renal Failure (CRF)Brazil
-
Mao JianhuaRecruitingAnemia Associated With Chronic Kidney DiseaseChina
-
FibroGenAstraZenecaWithdrawnAnemia Associated With Chronic Kidney DiseaseUnited States
Clinical Trials on roxadustat
-
Astellas Pharma IncFibroGenCompletedChronic Kidney DiseaseJapan
-
Astellas Pharma IncFibroGenCompletedESA-naive Hemodialysis Chronic Kidney Disease Patients With AnemiaJapan
-
Astellas Pharma IncFibroGenCompletedPeritoneal Dialysis Chronic Kidney Disease Patients With AnemiaJapan
-
Mao JianhuaRecruitingAnemia Associated With Chronic Kidney DiseaseChina
-
Sunshine Lake Pharma Co., Ltd.Nicoya Therapeutics (Shanghai) Co., Ltd.Not yet recruitingChronic Kidney Diseases | Renal AnemiaChina
-
FibroGenAstraZenecaWithdrawnAnemia Associated With Chronic Kidney DiseaseUnited States
-
FibroGenAstraZeneca; Astellas Pharma IncCompletedChemotherapy Induced AnemiaUnited States
-
Astellas Pharma Europe B.V.FibroGenCompletedImpaired Renal Function | Normal Renal FunctionGermany, United Kingdom
-
Astellas Pharma Global Development, Inc.FibroGenCompletedHealthy Adult SubjectsGermany
-
Astellas Pharma IncCompletedAnemia | Hemodialysis | Renal ImpairmentJapan